

MAY 27 2009

USSN 09/890,335
Response to Office Action mailed January 26, 2009
Amendment filed May 26, 2009

Amendments to the Specification

24-30

Please replace the paragraph occurring at page 1 lines ~~27-33~~ with the following amended paragraph:

Several documents are cited throughout the text of this specification. Each of the documents cited herein (including any manufacturer's specifications, instructions, etc.) are hereby incorporated by reference; however, there is no admission that any document cited is indeed prior art of the present invention. Further incorporated by reference is the complete disclosure content of the co-pending application filed in the name of IDEA AG and bearing the title "Transnasal transport/immunization with highly adaptable carriers" (U.S. Application No. 09/890,371, published as WO 2000/044350).

27

Please replace the paragraph occurring at page 14 line ~~36~~ to page 15 line 2 with the following amended paragraph:

For further definitions, especially such pertaining to the penetrants in terms of complex body deformability, the corresponding mechanism of action, lists of interesting penetrant ingredients or selected agents it is referred to the issued or pending patents (DE 41 07 152, PCT/EP91/01596 (published as WO/1992/003122 and equivalent to U.S. Patent No. 6,165,500 A), PCT/EP96/04526 (published as WO/1998/17255 and equivalent to U.S. Publication No. 2002/048596), DE 44 47 287). Detailed information relevant for the manufacturing process and penetrant loading with the antigenic (macro)molecules and/or immunoadjuvants, which are too big to permeate through the barrier, can be found in international patent application PCT/EP98/06750 (published as WO 00/24377 and equivalent to U.S. Publication No. 2008/279815).

24-30

Please replace the paragraph occurring at page 20 lines ~~26-32~~ with the following amended paragraph:

Basic formulations suitable for achieving the desired goals are known in the art: see, e.g., DE 41 07 152, PCT/EP91/01596 (published as WO/1992/003122 and equivalent to U.S. Patent No. 6,165,500 A), PCT/EP96/04526 (published as WO/1998/17255 and equivalent to U.S. Publication No. 2002/048596), DE 44 47 287, for more detailed or complementary information. The vaccine of this invention is not useful just for prophylactic or therapeutic vaccination but, moreover, is applicable for the treatment of allergy and for obtaining immunity against microbes, including extracellular and intercellular bacteria, viruses and parasites in the human and veterinary medicine.

12-13

Please replace the paragraph occurring at page 43 lines ~~16-17~~ with the following amended paragraph:

The effect discussed with examples 22-23 was confirmed also with a blend of different cytokines. The results are shown in figure 10.

USSN 09/890,335

Supplemental Amendment filed July 14, 2009

RECEIVED
CENTRAL FAX CENTER


JUL 14 2009

Amendments to the SpecificationPlease add the following new paragraph at page 1 line 2 of the application (immediately after the Title):Cross -Reference to Related Applications

This application is a national stage entry of PCT Application No. PCT/EP00/00597, filed January 26, 2000, which claims priority from European Patent Application No. EP 99101479, filed January 27, 1999.

JD
9/7/10
Please replace the paragraph occurring at page 15 line ³4 to page 16 line 2 as filed with the following paragraph:

Typically, the less soluble amongst the aggregating substances forming a carrier is a lipid or lipid-like material, especially a polar lipid, whereas the substance which is more soluble in the suspending liquid and which increases the droplet adaptability belongs to surfactants or else has surfactant-like properties. The former ingredient, typically, is a lipid or lipid-like material from a biological source or a corresponding synthetic lipid or any of its modifications, such lipid often belonging to the class of pure phospholipids with the chemical formula



where R_1 and R_2 is an aliphatic chain, typically a C_{10-20} -acyl, or -alkyl or partly unsaturated fatty acid residue, in particular, an oleoyl-, palmitocoyl-, lauroyl-, linoleyl-, linolenyl-, linolenoyl-, arachidoyl-, vacciny-, lauroyl-, myristoyl-, palmitoyl-, and stearoyl chain, and where R_3 is hydrogen, 2-trimethylamino-1-ethyl, 2-amino-1-ethyl, C_{1-4} -alkyl, C_{1-5} -alkyl substituted with carboxy, C_{2-5} -alkyl substituted with hydroxy, C_{2-5} -alkyl substituted with carboxy and hydroxy, or C_{2-5} -alkyl substituted with carboxy and amino, inositol, sphingosine, or salts of said substances, said lipid comprising also glycerides, isoprenoid lipids, steroids, sterines or sterols, of sulphur- or carbohydrate-containing lipids, or any other bilayer forming lipids, in particular half-protonated fluid fatty acids, and preferably is selected from the group of phosphatidylcholines, phosphatidylethanolamines, phosphatidylglycerols, phosphatidylinositols, phosphatidic acids, phosphatidylserines, sphingomyelins or other